









HEMATOLOGY, TRANSFUSION AND CELL THERAPY

www.htct.com.br


Original article

Functional capacity in sickle cell disease: A pilot study with 1-minute sit-to-stand test

Q1 Michele Barroso Thomaz ^{a,*}, Lucas Fernandes Suassuna ^b,
 Júlia Campos Fabri ^b, Isabela de Oliveira Araújo ^b,
 Q2 Júlia Carneiro Almeida ^a, Daniela de Oliveira Werneck Rodrigues ^a

^a Fundação Hemominas, Juiz de Fora, MG, Brazil

^b Universidade Federal de Juiz de Fora (UFJF), Juiz de Fora, MG, Brazil

ARTICLE INFO

Article history:

Received 19 October 2024

Accepted 21 October 2025

Available online xxx

Edited by Eduardo Rego.

Keywords:

Functional status

Sickle cell disease

Quality of life

1-minute sit-to-stand test

ABSTRACT

Background: Sickle cell disease, the most prevalent monogenic recessive genetic disorder in the world, is characterized by two main pathogenic mechanisms: vaso-occlusion and hemolysis. These characteristics lead to reduced tolerance to physical exertion and, consequently, a reduced functional capacity which can be assessed using the one-minute sit-to-stand test. Complications from sickle cell disease result in poor quality of life, increased absenteeism from school and work, and impaired social interaction.

Method: Between January 2023 and April 2024, a pilot cross-sectional study was conducted with sickle cell disease patients aged from 18 to 60 years. The one-minute sit-to-stand test, Borg's perceived exertion scale, and the SF-36 quality of life questionnaire were utilized. Patients were monitored during the test. The sample was dichotomized based on test performance and SF-36 scores. Furthermore, clinical and demographic variables were analyzed.

Main results: Fifty-eight individuals participated in the final analysis. The mean age was 29.84 ± 11.20 years; 55.1 % were men, and 79.3 % identified themselves as Black or mixed race. The most prevalent genotype was hemoglobin SS (67.2 %), and 77.5 % were taking Hydroxyurea. The group with a better performance in the one-minute sit-to-stand test showed better quality of life as assessed using the SF-36 questionnaire.

Conclusion: Functional capacity is a significant factor in the autonomy and quality of life of patients with sickle cell disease. The one-minute sit-to-stand test is a low-cost and easily applicable test, which can contribute to the assessment of functional capacity in the routine follow-up of these patients.

© 2025 Published by Elsevier España, S.L.U. on behalf of Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

* Corresponding author at: Rua Barão de Cataguase s/n, Juiz de Fora Minas Gerais Brazil, CEP, Brazil.

E-mail address: michellethoomaz@gmail.com (M.B. Thomaz).

<https://doi.org/10.1016/j.htct.2025.106230>

2531-1379/© 2025 Published by Elsevier España, S.L.U. on behalf of Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1 Introduction

2 Sickle cell disease (SCD), resulting from a mutation in the
3 hemoglobin (Hb) gene that leads to the formation of Hb S, is
4 the most prevalent recessive monogenic disease in the world.
5 There are multiple genotypes that cause SCD including the
6 severe homozygous form, Hb SS, or as heterozygous forms
7 with other hemoglobin variants, such as Hb C or Hb β -thalas-
8 semia [1].

9 When deoxygenated, Hb S polymerizes and modifies the
10 morphology of red blood cells making their membrane rigid
11 and into a sickle shape. This modified state favors the occur-
12 rence of vaso-occlusive crises (VOC), endothelial dysfunction,
13 hemolysis, and activation of inflammatory responses through
14 the release of cytokines and reactive oxygen species. VOC
15 lead to ischemia and are the main factor responsible for pain
16 crises in SCD as well as other complications, such as acute
17 chest syndrome and osteonecrosis. Endothelial dysfunction
18 is associated with intravascular hemolysis, nitric oxide deple-
19 tion and hypercoagulability, and is the underlying mecha-
20 nism of complications such as strokes, pulmonary
21 hypertension and organ damage, especially of the kidneys
22 and heart [1,2].

23 The complex physiopathology of SCD reduces tolerance to
24 physical exertion, which is seen by a reduced functional
25 capacity (FC). The acute complications of SCD result in school
26 and work absenteeism, negative impacts on socialization and
27 a low quality of life. Therapeutic exercise is an important tool
28 for rehabilitation in SCD, recovering cardiorespiratory capac-
29 ity and autonomy, and improving socialization. However, the
30 prescription of exercise in SCD is a highly complex topic and
31 may cause VOC if excessively intense [2].

32 Assessing FC is crucial for developing an appropriate
33 exercise prescription, as a wide array of functional assess-
34 ment tools, ranging from simple field tests to sophisticated
35 laboratory procedures, is available. The cardiopulmonary
36 exercise test (CPET) is the gold standard; however, it requires
37 specific, costly equipment that limits its availability [3].
38 Other methods for functional assessment consist in field
39 tests, which include the ergometric test, Bruce protocol, 6-
40 Minute Walk Test (6MWT), and the 1-Minute Sit-to-Stand
41 test (1-MSTST) [4,5]. The 1-MSTST is a submaximal test vali-
42 dated for assessing FC, postural control, proprioception, and
43 lower limb strength. It is a well-tolerated, low-cost test that
44 can be applied domestically, at the bedside and in small
45 rooms as it only requires an armless chair, a stopwatch and
46 minimal floor space [6,7]. To the present moment, there are
47 no studies assessing FC in SCD patients utilizing the 1-
48 MSTST.

49 Objective

50 The objective of this study is to assess FC in adult SCD
51 patients using the 1-MSTST test, and to evaluate possible
52 associations between the FC, quality of life, and clinical and
53 demographic variables.

Method

54 This cross-sectional pilot study to assess FC in SCD patients
55 using the 1-MSTST was carried out between January and April
56 2024. Participants were active patients in a secondary care
57 facility specialized in hematology and hemotherapy. Adults
58 aged between 18 and 60 years, diagnosed with SCD, who
59 signed an informed consent form, participated in the study.
60 Exclusion criteria were: refusal to participate; clinical events
61 during the 1-MSTST; a drop in oxygen saturation >4 % during
62 the 1-MSTST; systolic blood pressure >180 mmHg or diastolic
63 blood pressure >110 mmHg; unstable angina; resting heart
64 rate >120 bpm; and orthopedic conditions that limited perfor-
65 mance in the 1-MSTST.

66 The instruments utilized for this study were: the 1-MSTST
67 test, the Borg rate of perceived exertion scale for the assess-
68 ment of work of breathing, [8] and the Short Form 36 Health
69 Survey Questionnaire, [9] which is divided in eight domains
70 (Physical functioning; physical role limitations; bodily pain;
71 general health perceptions; energy/vitality; social function-
72 ing; emotional role limitations; and mental health) and two
73 summary measures (physical component summary and men-
74 tal component summary). All anthropometric and clinical
75 data were collected with standardized equipment and all
76 tests were performed supervised by trained research staff. A
77 brochure containing information about lifestyle changes and
78 possible physical activities was created by the research staff
79 and handed to the study participants.

80 Initially, a descriptive analysis was performed utilizing the
81 adequate frequency and central tendency measures. The
82 study by Strassman et al. was utilized to obtain the age-cor-
83 rected target repetitions for the 1-MSTST [10] by which our
84 sample was standardized. For the comparative analysis, the
85 sample was divided in two groups based on the median 1-
86 MSTST performance, and analyzed with Student's t-test and
87 Pearson's chi-squared test. The variables included in the
88 analysis were age, gender, ethnicity, SCD genotype, use of
89 hydroxyurea, 1-MSTST performance, baseline and post-inter-
90 vention heart rate, baseline and post-intervention peripheral
91 oxygen saturation, and baseline and post-intervention Borg
92 scale. The software IBM SPSS Statistics 25[®] was utilized for
93 the statistical analysis. This study was registered and
94 approved by the institution's research ethics committee
95 under the number CAAE 63,424,422.9.0000.5118.

Results

97 In total, 85 individuals met the inclusion criteria of the study;
98 however, 27 were later excluded, as nine had a diagnosis of
99 hip osteonecrosis, eight did not complete the SF-36 health
100 survey questionnaire, six presented with lower body pain
101 during the clinical assessment and four refused to participate.
102 After the 58 participants performed the 1-MSTST, the sample
103 was divided in two groups based on the median performance
104 (20.75 repetitions): 28 patients had an above median perfor-
105 mance and 30 patients had a below median performance
106 (Figure 1).




Figure 1 – Study flowchart.

Of the 58 participants, the average age was 29.84 ± 11.20 years with ages ranging between 18 and 59 years, 55.1 % were male, and 79.3 % identified themselves as Black. The most frequent genotype was Hb SS ($n = 39$; 67.2 %) and 77.5 % of the sample was taking hydroxyurea. In the comparative analysis, the group with the best 1-MSTST performance had a statistical tendency to be younger (p -value = 0.08), and had a higher post-intervention heart rate (p -value = 0.001). The other analyzed variables were not statistically significant, such as use of hydroxyurea and disease genotype (Table 1).

The data regarding the results of the SF-36 health survey analysis are found in Table 2. The group with a worse performance in the 1-MSTST had statistically significant lower scores in the physical component summary (p -value = 0.05),

mental health (p -value = 0.01) and general health perceptions (p -value = 0.02). Other SF-36 health survey dimensions, such as physical role limitations (p -value = 0.07) and physical functioning (p -value = 0.09) approached statistical significance for a worse score in the group with the worst performance.

Discussion

SCD is one the most epidemiologically relevant hematological conditions in the world. In Brazil it represents an important health burden, affecting an estimated 60,000–100,000 people [11]. Between 2014 and 2020, an annual average of 1087 people were born with the disease in Brazil, with an incidence of 3.75

Table 1 – Demographic and clinical variables of the sample categorized by 1-MSTST performance.

Variable	Total	Median performance		p-value
		<20.75 repetitions (n = 30)	>20.75 repetitions (n = 28)	
Age (mean)	29.84 ± 11.20	32.27 ± 11.95	27.25 ± 9.89	0.08
Gender, male – n (%)	32 (55.1)	15 (50)	17 (60.7)	0.41
Race, black – n (%)	46 (79.3)	24 (80)	22 (78.6)	0.57
Genotype – n (%)				0.75
Hb SS	39 (67.2)	20 (66.7)	19 (67.9)	
Hb S β ⁺	9 (15.5)	5 (16.7)	4 (14.3)	
Hb SC	9 (15.5)	4 (13.3)	5 (17.9)	
Hb S β ⁰	1 (1.7)	1 (3.3)	0 (0)	
Medication				
Hydroxyurea use	45 (77.5 %)	23 (76.7 %)	22 (78.6 %)	0.86
Average dosage (mg)	1130.16 ± 360.57	1133.70 ± 400.36	1126.45 ± 323.19	0.94
1-MSTST				
Repetitions	20.44 ± 5.88	15.96 ± 3.86	25.25 ± 3.29	<0.001*
Target/real performance ratio (%)	43.86 ± 11.79	34.94 ± 7.51	53.42 ± 7.07	<0.001*
Baseline heart rate (bpm)	78.69 ± 13.10	76.66 ± 11.28	80.87 ± 14.70	0.22
Post intervention heart rate (bpm)	121.05 ± 20.42	112.73 ± 20.84	129.96 ± 15.95	0.001*
Baseline O ₂ saturation (%)	93.68 ± 4.01	93.43 ± 4.57	93.96 ± 3.36	0.61
Post intervention O ₂ saturation (%)	92.81 ± 4.39	92.70 ± 5.22	92.94 ± 3.37	0.83
Baseline Borg	1.61 (0 - 2.12)	1.85	1.35	0.36
Post intervention Borg	5 ± 2.13	5.1 ± 2.37	4.89 ± 1.88	0.71

1-MSTST: 1-minute sit-to-stand test.

Table 2 – Results of SF-36 health survey analysis categorized by 1-MSTST performance.

SF-36	Total	Median performance		p-value
		<20.75 repetitions (n = 30)	>20.75 repetitions (n = 28)	
PCS	44.45 ± 9.74	42.12 ± 9.27	46.95 ± 9.76	0.05
MCS	47.97 ± 12.38	45.39 ± 13.23	50.73 ± 10.96	0.10
Physical functioning	72.98 ± 20.82	68.16 ± 20.11	77.50 ± 21.01	0.09
Physical role limitations	60.52 ± 44.30	52.50 ± 45.65	73.21 ± 39.63	0.07
Emotional role limitations	68.41 ± 38.03	60.00 ± 40.49	73.80 ± 37.79	0.18
Energy/vitality	59.91 ± 28.30	54.33 ± 25.68	63.39 ± 29.44	0.21
Mental health	68.70 ± 25.51	61.86 ± 25.70	76.71 ± 20.07	0.01*
Social functioning	79.60 ± 29.37	76.66 ± 30.21	83.48 ± 28.06	0.37
Bodily pain	76.57 ± 30.23	66.30 ± 33.52	78.78 ± 29.30	0.13
General health perceptions	50.70 ± 25.16	44.86 ± 20.53	59.32 ± 26.27	0.02*

SF-36: SF-36 health survey questionnaire; PCS: Physical component summary; MCS: Mental component summary.

cases per 10,000 newborns [12]. SCD represents a challenge for the Brazilian public health system due to its complex pathophysiology, need for interdisciplinary care, and socio-economic impact. Historically, newborn screening and continued health education, in addition to regular medical care, have been effective strategies for reducing complications and increasing quality of life for SCD patients in Brazil [1].

Patients were not included in the analysis of this study if they presented with conditions that could interfere with their performance in the 1-MSTST, the most prevalent of which was hip osteonecrosis, with a frequency of 10.58 %. Osteonecrosis is a frequent complication of SCD that occurs due to VOC with the most frequent sites being the hips, vertebrae and shoulders [13]. The prevalence of osteoarticular involvement increases with age. Ouederni et al. found a prevalence of hip osteonecrosis of 18.3 % in 20-year-old SCD patients, compared to a 2.3 % hip osteonecrosis prevalence in 10-year-olds [14,15]. Daltro et al. reported a prevalence of osteonecrosis in 11.1 % of SCD patients in Brazil, most frequently of the hip joint (74.6 %), [15] a result similar to the current findings.

Regarding the SCD genotype, 67.1 % of the present sample had the Hb SS genotype, a proportion similar to other Brazilian studies, such as Silva et al., whose group identified a slightly greater prevalence of Hb SS, at 75 % [16]. Souza et al. identified a lower prevalence of 60 % in their sample with Hb SS [17]. These variations are common and reflect differences in recruiting methods and populations. Cardoso et al. found a median age of 28.6 ± 9.9 years and a 65 % prevalence of Hb SS, very similar results to this study [18]. These findings reinforce the representativeness of the current sample. The different genotypes of SCD correlate to disease severity and symptomatology: Hb S β^+ -thalassemia and Hb SC are considered of mild severity, while Hb SS and Hb S β^0 -thalassemia present a greater clinical relevance and severity [19]. In this study, the SCD genotype was not significantly associated with worse 1-MSTST performance, possibly due to the high proportion of Hb SS in the sample (n = 39; 67.2 %).

A worse performance in the 1-MSTST was observed among older participants (p-value = 0.08), which may be explained by the buildup of osteoarticular and inflammatory damage caused by SCD and aging. Other sociodemographic

variables, such as gender and ethnicity, were not statistically significant in this study. Hydroxyurea is the most efficient pharmacological therapy for SCD available in Brazil; its use is associated with a lower rate of degenerative damage [19,20]. In the present study, 77.5 % of the participants were in continuous use of hydroxyurea; however, its use was not associated with a better performance in the 1-MSTST (p-value = 0.86). The authors did not find any literature regarding 1-MSTST performance and use of hydroxyurea, or other drugs, among SCD patients.

No participants of this study were capable of reaching their age-corrected performance target for the 1-MSTST. Studies utilizing other methods to assess FC in SCD patients present with similar results. Cardoso et al. assessing the FC in an adult population with sickle cell anemia utilizing the 6MWT found that the average distance covered by study participants was less than the expected target distance for the Brazilian population (335.3 ± 70.6 m versus 504.7 ± 5.5 m; p-value <0.001) [21]. The 1-MSTST is a low-cost, simple assessment that can be applied in domestic and bedside environments; it provides a similar hemodynamic and ventilatory response to the 6MWT, which is considered the gold-standard field FC assessment tool. There are no studies utilizing the 1-MSTST to assess FC in SCD, which is a limiting factor of the present discussion.

The association between quality of life and FC is evident in several health conditions, including SCD, in which individuals present with decreased tolerance to physical exertion, resulting in loss of muscle mass and adverse psychosocial effects. In addition, it is common for SCD patients to be advised to avoid physical activities, leading to a sedentary lifestyle and increasing adverse psychosocial and body composition effects [22–24]. A study with SCD patients implemented an eight-week exercise program, with results showing increases in both the FC and quality of life assessed by the SF-36 health survey [23]. The present study found that a worse performance in the 1-MSTST was associated with a worse quality of life assessed by the SF-36 health survey questionnaire. Therefore, in patients with physical disabilities caused by SCD, an approach focused on mental health, in addition to physical training, is of utmost importance, as anxiety and depressive symptoms are very common in this population [24].

Conclusion

In this study, a better performance in the 1-MSTST was associated with a better quality of life assessed using the SF-36 health survey, however there was no statistical association with any of the clinical and demographic variables. The 1-MSTST, a low cost and easily applicable tool for FC assessment, could be a useful addition to the physical evaluation of SCD patients. The multidisciplinary team could use this test for triage during routine follow-ups and stimulate early physical health interventions for the purpose of reducing morbidity associated with SCD.

Conflicts of interest

None.

REFERENCES

- [1]. Kavanagh PL, Fasipe TA, Wun T. Sick cell disease: a review. *JAMA*. 2022;328(1):57–68.
- [2]. Pinto DMR, et al. Physical exercise in sickle cell anemia: a systematic review. *Hematol Transfus Cell Ther*. 2021;43(3):324–31.
- [3]. Smith KN, Baynard T, Fischbach PA, Hankins JS, Hsu LL, Murphy PM, et al. Safety of maximal cardiopulmonary exercise testing in individuals with sickle cell disease: a systematic review. *Br J Sports Med*. 2022 Jul;56(13):764–9.
- [4]. JÁ Araujo Junior, DAA Rossi, Valadão TFC, Mattos JCM, Catai AM, Sato TO, et al. Cardiovascular benefits of a home-based exercise program in patients with sickle cell disease. *Plos One*. 2021;16(5):0250128. 12.
- [5]. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. *Am J of Respir Crit Care Med*. 2002;166:111–7. <https://doi.org/10.1164/rccm.166/1/111>.
- [6]. Pereira MC, Lima LNG, Moreira MM, Mendes FAR. One minute sit-to-stand test as an alternative to measure functional capacity in patients with pulmonary arterial hypertension. *J Bras Pneumol*. 2022;48(3):20210483.
- [7]. Reyhler G, Pincin L, Audag N, Poncin W, Caty G. One-minute sit-to-stand test as an alternative tool to assess the quadriceps muscle strength in children. *Respir Med Res*. 2020;78:100777.
- [8]. Loss LC, Born PL, Wolf R, Stefanello JMF, Pereira G. A systematic review of cross-cultural adaptation and validation of Borg's Rating of perceived exertion scale. *J Phys Educ*. 2017;28:e2853. <https://doi.org/10.4025/jphyseduc.v28i1.2853>.
- [9]. Ciconelli RM, Ferraz MB, Santos W, Meinão I, Quaresma MR. Tradução para a língua portuguesa e validação do questionário genérico de avaliação de qualidade de vida SF-36 (Brasil SF-36). *Rev Bras Reumatol*. 1999;39(3):143–50.
- [10]. Strassman A, Steurer-Stey C, Lana KD, Zoller M, Turk AJ, Paolo Suter, et al. Population-based reference values for the

- 1-min sit-to-stand test. *Int J Public Health*. 2013;58(6):949–53. <https://doi.org/10.1007/s00038-013-0504-z>.
- [11]. GBD 2021 Sickle Cell Disease Collaborators. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021. *Lancet Haematol*. 2023;10:e585–99.
- [12]. Ministério da Saúde. Doença Falciforme. Disponível em Acesso em: 18 de abril de <https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/d/doencafalciforme#:~:text=Estima/2Dse/20que/20h/C3/A1/2060.000,unidades/20federa-das/20de/20maior/20incid/C3/AAncia>; 2024 Acesso em: 18 de abril de.
- [13]. Almeida A, Roberts I. Bone involvement in sickle cell disease. *Br. J. Haematol*. 2005;129:482–90.
- [14]. Daltro G, Franco BA, Faleiro TB, Rosário DAV, Daltro PB, Fortuna V. Osteonecrosis in sickle cell disease patients from Bahia, Brazil: a cross-sectional study. *Int Orthop*. 2018 Jul;42(7):1527–34.
- [15]. Ouederni M, Rouge H, Fraj IB, Rekaya S, Kouki R, Lamouchi T, et al. Incidence and risk factors for osteonecrosis of the femoral head in five hundred and ten sickle cell disease paediatric patients. *Int Orthop*. 2023 Dec;47(12):2941–52.
- [16]. Silva AC, et al. Demographic and clinical profile of patients with sickle cell disease in a referral center. *J. Hematol*. 2015;5(3):101–7.
- [17]. Souza FG, et al. Sickle cell disease in adults: a comprehensive review of epidemiological data. *Blood Rev*. 2017;31(1):20–6.
- [18]. Cardoso GP, et al. Functional capacity and its determinants in patients with sickle cell anemia. *Braz. J. Med. Biol. Res*. 2019;52(3):e7881.
- [19]. BRASIL. Ministério da Saúde. Secretaria de Atenção à Saúde. Secretaria de ciência, tecnologia e insumos estratégicos. Portaria conjunta no 05, de 19 de fevereiro de 2018. Aprova o protocolo clínico e diretrizes terapêuticas da doença falciforme. Brasília (Distrito Federal); 2018.
- [20]. Khargekar N, Banerjee A, Athalye S, Mahajan N, Kargutkar N, Tapase P, et al. Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: a systematic review and meta-analysis. *Syst Rev*. 2024;13(1):60.
- [21]. Cardoso LR, Rodrigues EM, Oliva MVCS, Martinez BP, Pires TQ. Capacidade funcional em pacientes com doença falciforme em Salvador-BA. *ASSOBRAFIR Ciência*. 2016;7:23–30.
- [22]. Antonelli Rossi DA, De Araujo Junior JA, Luvizutto GJ, Bazan R, Salmazo PS, Modolo GP, et al. Effect of a physical exercise program on the inflammatory response, cardiac functions, functional capacity, and quality of life in patients with sickle cell disease. *J Clin Med*. 2023 Jun 9;12(12):3952.
- [23]. Almeida CHS, Reis LFDF, Nascimento LPADS, Soares AR, Maioli MCP, Lopes AJ. Therapist-oriented home rehabilitation for adults with sickle cell anemia: effects on muscle strength, functional capacity, and quality of life. *Hematology*. 2021 Dec;26(1):612–9. <https://doi.org/10.1080/16078454.2021.1965736>. PMID: 34411499.
- [24]. Dos Santos JP, Gomes Neto M. Sociodemographic aspects and quality of life of patients with sickle cell anemia. *Rev Bras Hematol Hemoter*. 2013;35(4):242–5. <https://doi.org/10.5581/1516-8484.20130093>. PMID: 24106440; PMCID: PMC3789427.